Ji Zheng Chen
Director/Board Member at SINOCARE INC.
Ji Zheng Chen active positions
| Companies | Position | Start | End |
|---|---|---|---|
| SINOCARE INC. | Director/Board Member | 30/08/2023 | - |
| Independent Dir/Board Member | 30/08/2023 | - | |
Denovo Biopharma Co., Ltd.
 Denovo Biopharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Denovo Biopharma Co., Ltd. is a clinical-stage biopharmaceutical company based in Beijing, China. Denovo Biopharma uses novel biomarker approaches to execute efficient clinical trials in targeted patient populations to optimize the probability of successful trials. The Chinese company has eight late clinical stage drugs in its pipeline addressing major unmet medical needs in oncology and CNS diseases, most of which are first-in-class drugs with rights. Denovo Biopharma seeks to discover genomic biomarkers correlated with patients' responses to drug candidates retrospectively. The company designs and executes efficient clinical trials in targeted patient populations to optimize the probability of a successful trial. Denovo Biopharma is enrolling patients in a phase 3 clinical trial for its lead asset db102 (enzastaurin) in diffuse large B-cell lymphoma (DLBCL) and will start a phase 2b study in glioblastoma (GBM). The company has four additional late-stage programs targeting major unmet needs\: db103 for schizophrenia, db104 for depression, db105 for Alzheimer's disease, and db106 for acute myeloid leukemia (AML). Denovo Biopharma is a next-generation biomarker partner to personalize your drug. The company was founded in 2012 by Wen Luo. | Director/Board Member | - | - |
| Director of Finance/CFO | - | - | |
| Corporate Secretary | - | - |
Career history of Ji Zheng Chen
Training of Ji Zheng Chen
| National Chengchi University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistics
International
| China | 3 |
| Taiwan | 2 |
| United States | 2 |
Operational
| Director/Board Member | 2 |
| Director of Finance/CFO | 1 |
| Corporate Secretary | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| SINOCARE INC. | Health Technology |
| Private companies | 1 |
|---|---|
Denovo Biopharma Co., Ltd.
Denovo Biopharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Denovo Biopharma Co., Ltd. is a clinical-stage biopharmaceutical company based in Beijing, China. Denovo Biopharma uses novel biomarker approaches to execute efficient clinical trials in targeted patient populations to optimize the probability of successful trials. The Chinese company has eight late clinical stage drugs in its pipeline addressing major unmet medical needs in oncology and CNS diseases, most of which are first-in-class drugs with rights. Denovo Biopharma seeks to discover genomic biomarkers correlated with patients' responses to drug candidates retrospectively. The company designs and executes efficient clinical trials in targeted patient populations to optimize the probability of a successful trial. Denovo Biopharma is enrolling patients in a phase 3 clinical trial for its lead asset db102 (enzastaurin) in diffuse large B-cell lymphoma (DLBCL) and will start a phase 2b study in glioblastoma (GBM). The company has four additional late-stage programs targeting major unmet needs\: db103 for schizophrenia, db104 for depression, db105 for Alzheimer's disease, and db106 for acute myeloid leukemia (AML). Denovo Biopharma is a next-generation biomarker partner to personalize your drug. The company was founded in 2012 by Wen Luo. | Health Technology |
- Stock Market
- Insiders
- Ji Zheng Chen
- Experience